Table 4.
Pharmacokinetic parameters of gefitinib and gefitinib nanosuspension after oral administration
| Pharmacokinetic parameters | Standard* | Gefitinib nanosuspension* |
|---|---|---|
| Cmax (ng/mL) | 29,293.58±4,880.04 | 46,211.04±5,805.97 |
| Tmax (h) | 4±1.16 | 6.67±1.77 |
| Half-life (h) | 10.96±0.34 | 8.65±1.99 |
| Ke (1/h) | 0.04±0.02 | 0.09±0.02 |
| Vd (mL) | 179.13±9.70 | 78.77±17.78 |
| Cl (mL/h) | 11.32±0.48 | 6.32±0.21 |
| AUC(0–t) (ng·h/mL) | 485,344.50±21,005.59 | 879,447.90±28,982.27 |
| AUC(0–infinity) (ng·h/mL) | 498,068.20±20,689.72 | 888,923.10±28,841.79 |
| MRT0–t (h) | 25.29±0.74 | 20.18±0.63 |
| MRT0–∞ (h) | 26.89±0.86 | 20.88±0.67 |
Notes:
*
Data presented as mean ± SEM, n=3. Cmax, peak plasma concentration; Tmax, time to achieve peak plasma concentration; Ke, elimination rate constant; Vd, volume of distribution; AUC0–t, area under the curve from time of administration to time “t”; AUC(0–infinity), area under the curve from time of administration until infinite time elapse.
Abbreviations: Cl, clearance; SEM, standard error of mean; MRT, mean residence time.